Extra Corporeal Membrane Oxygenation (ECMO) System Market Size

Extra Corporeal Membrane Oxygenation (ECMO) System Market Analysis

The extracorporeal membrane oxygenation (ECMO) system market is projected to register a CAGR of 4.71% over the forecast period.

COVID-19 significantly impacted the market growth. For instance, according to an article published in BioMed Central, in September 2021, mortality for ECMO-supported patients with COVID-19 significantly worsened worldwide throughout the pandemic, and the duration of ECMO support increased. These unpredictable results necessitated ongoing monitoring, understanding of local and regional death rates, the length of ECMO support, and possible resource limitations. Also, the risk of severe COVID-19 in people with asthma was relatively small. Still, people with chronic obstructive pulmonary disorders and interstitial lung disease had a moderate risk of severe disease due to COVID-19. Thus, the pandemic impacted market growth during the pandemic. However, with removed restrictions and trade barriers, the supply chain of ECMO machines increased, further propelling the market growth.

Factors such as the increasing prevalence of cardiovascular and respiratory diseases, technological advancements in ECMO technology, and increased adoption of ECMO systems are expected to boost market growth over the forecast period.

The increasing burden of respiratory and cardiovascular disease among the population increased the demand for ECMO systems due to insufficient oxygen supply to the body. For instance, according to the study published in the PLOS One journal in January 2021, it was observed that about 2.6 million people were suffering from chronic obstructive pulmonary disease (COPD) in France, and this number is expected to rise to 2.8 million by 2025. Additionally, according to the 2022 statistics published by the Australian Bureau of Statistics, the prevalence of heart disease in Australia was 4.0% in 2020-2021, which equates to about 1 million people.

Furthermore, hospitals' rising adoption of ECMO machines increased their demand, which is also expected to fuel the market growth over the forecast period. For instance, as per an article published in NLM in April 2022, it was observed that 151,683 patients, including 45,205 newborns, 30,743 children, and 75,735 adults, received ECMO treatment during the pandemic period. In addition, 492 centers and hospitals adopted ECMO machines during the pandemic.

Moreover, the rising product launches increase the availability of technologically advanced ECMO systems in the market. It is expected to fuel the market growth over the forecast period. For instance, in October 2021, Getinge launched the Rotaflow II Extracorporeal Life Support (ECLS) System with the Permanent Life Support (PLS) Set, which offers up to 14 days of cardiopulmonary support in a compact, portable, safe, and reliable manner. It gives healthcare staff the flexibility they need to provide quality patient care.

Therefore, the studied market is expected to grow over the forecast period due to the factors above, such as the high burden of cardiopulmonary diseases, the growing adoption of ECMO systems, and increasing product launches. However, the high cost of ECMO procedures and the risk associated with ECMO systems will likely impede the growth of the extracorporeal membrane oxygenation (ECMO) system market over the forecast period.